Combination of myostatin pathway interference and dystrophin rescue enhances tetanic and specific force in dystrophic mdx mice

Molecular Therapy

Volumn 18, Issue 5, 2010, Pages 881-887

  Dumonceaux, Julie ^a   Marie, Solenne ^a   Beley, Cyriaque ^a   Trollet, Capucine ^a   Vignaud, Alban ^a   Ferry, Arnaud ^a   Butler Browne, Gillian ^a   Garcia, Luis ^a  

^a Groupe Hospitalier Pitié Salpêtrière   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVIN RECEPTOR 2B; CYTOKINE RECEPTOR; DYSTROPHIN; MESSENGER RNA; MYOSTATIN; MYOSTATIN RECEPTOR; PARVOVIRUS VECTOR; SHORT HAIRPIN RNA; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL STRAIN HEK293; CONTROLLED STUDY; DRUG TARGETING; DUCHENNE MUSCULAR DYSTROPHY; EXON SKIPPING; FEMALE; GENE EXPRESSION REGULATION; HISTOPATHOLOGY; HUMAN; HUMAN CELL; MOUSE; MUSCLE ATROPHY; MUSCLE FORCE; MUSCLE MASS; MUSCLE METABOLISM; MUSCLE TETANIC CONTRACTION; NONHUMAN; PHARMACOGENETICS; RECEPTOR DOWN REGULATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA INTERFERENCE; TIBIALIS ANTERIOR MUSCLE; X CHROMOSOME LINKED MUSCULAR DYSTROPHIC MOUSE;

ACTIVIN RECEPTORS, TYPE II; ANIMALS; CELL LINE; DEPENDOVIRUS; DYSTROPHIN; FEMALE; GENETIC VECTORS; HUMANS; MICE; MICE, INBRED MDX; MUSCULAR DYSTROPHY, DUCHENNE; MYOSTATIN; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA INTERFERENCE; SIGNAL TRANSDUCTION;

MUS;

EID: 77952011904     PISSN: 15250016     EISSN: 15250024     Source Type: Journal    
DOI: 10.1038/mt.2009.322     Document Type: Article

References (49)

1. Lu, QL, Rabinowitz, A, Chen, YC, Yokota, T, Yin, H, Alter, J et al. (2005). Systemic delivery of antisense oligoribonucleotide restores dystrophin expression in body-wide skeletal muscles. Proc Natl Acad Sci USA 102:198-203.
2. Alter, J, Lou, F, Rabinowitz, A, Yin, H, Rosenfeld, J, Wilton, SD et al. (2006). Systemic delivery of morpholino oligonucleotide restores dystrophin expression bodywide and improves dystrophic pathology. Nat Med 12:175-177.
3. Fletcher, S, Honeyman, K, Fall, AM, Harding, PL, Johnsen, RD and Wilton, SD (2006). Dystrophin expression in the mdx mouse after localised and systemic administration of a morpholino antisense oligonucleotide. J Gene Med 8:207-216.
4. Lu, QL, Mann, CJ, Lou, F, Bou-Gharios, G, Morris, GE, Xue, SA et al. (2003). Functional amounts of dystrophin produced by skipping the mutated exon in the mdx dystrophic mouse. Nat Med 9:1009-1014.
5. McClorey, G, Moulton, HM, Iversen, PL, Fletcher, S and Wilton, SD (2006). Antisense oligonucleotide-induced exon skipping restores dystrophin expression in vitro in a canine model of DMD. Gene Ther 13:1373-1381.
6. Yokota, T, Lu, QL, Partridge, T, Kobayashi, M, Nakamura, A, Takeda, S et al. (2009). Efficacy of systemic morpholino exon-skipping in Duchenne dystrophy dogs. Ann Neurol 65:667-676.
7. Wu, B, Lu, P, Benrashid, E, Malik, S, Ashar, J, Doran, TJ et al. (2009). Dose-dependent restoration of dystrophin expression in cardiac muscle of dystrophic mice by systemically delivered morpholino. Gene Ther (epub ahead of print).
8. Kinali, M, Arechavala-Gomeza, V, Feng, L, Cirak, S, Hunt, D, Adkin, C et al. (2009). Local restoration of dystrophin expression with the morpholino oligomer AVI-4658 in Duchenne muscular dystrophy: a single-blind, placebo-controlled, dose-escalation, proof-of-concept study. Lancet Neurol 8:918-928.
9. Goyenvalle, A, Vulin, A, Fougerousse, F, Leturcq, F, Kaplan, JC, Garcia, L et al. (2004). Rescue of dystrophic muscle through U7 snRNA-mediated exon skipping. Science 306:1796-1799.
10. Denti, MA, Rosa, A, D'Antona, G, Sthandier, O, De Angelis, FG, Nicoletti, C et al. (2006). Chimeric adeno-associated virus/antisense U1 small nuclear RNA effectively rescues dystrophin synthesis and muscle function by local treatment of mdx mice. Hum Gene Ther 17:565-574.
11. Barberi, L, Dobrowolny, G, Pelosi, L, Giacinti, C and Musarò, A (2009). Muscle involvement and IGF-1 signaling in genetic disorders: new therapeutic approaches. Endocr Dev 14:29-37.
12. Negroni, E, Butler-Browne, GS and Mouly, V (2006). Myogenic stem cells: regeneration and cell therapy in human skeletal muscle. Pathol Biol (Paris) 54:100-108.
13. Péault, B, Rudnicki, M, Torrente, Y, Cossu, G, Tremblay, JP, Partridge, T et al. (2007). Stem and progenitor cells in skeletal muscle development, maintenance, and therapy. Mol Ther 15:867-877. (Pubitemid 46621645)
14. Kambadur, R, Sharma, M, Smith, TP and Bass, JJ (1997). Mutations in myostatin (GDF8) in double-muscled Belgian Blue and Piedmontese cattle. Genome Res 7:910-916.
15. McPherron, AC and Lee, SJ (1997). Double muscling in cattle due to mutations in the myostatin gene. Proc Natl Acad Sci USA 94:12457-12461.
16. Grobet, L, Poncelet, D, Royo, LJ, Brouwers, B, Pirottin, D, Michaux, C et al. (1998). Molecular definition of an allelic series of mutations disrupting the myostatin function and causing double-muscling in cattle. Mamm Genome 9:210-213.
17. Clop, A, Marcq, F, Takeda, H, Pirottin, D, Tordoir, X, Bibé, B et al. (2006). A mutation creating a potential illegitimate microRNA target site in the myostatin gene affects muscularity in sheep. Nat Genet 38:813-818.
18. Mosher, DS, Quignon, P, Bustamante, CD, Sutter, NB, Mellersh, CS, Parker, HG et al. (2007). A mutation in the myostatin gene increases muscle mass and enhances racing performance in heterozygote dogs. PLoS Genet 3: e79.
19. Schuelke, M, Wagner, KR, Stolz, LE, Hübner, C, Riebel, T, Kömen, W et al. (2004). Myostatin mutation associated with gross muscle hypertrophy in a child. N Engl J Med 350:2682-2688.
20. Lee, SJ (2004). Regulation of muscle mass by myostatin. Annu Rev Cell Dev Biol 20:61-86.
21. Lee, SJ and McPherron, AC (2001). Regulation of myostatin activity and muscle growth. Proc Natl Acad Sci USA 98:9306-9311.
22. Bogdanovich, S, Krag, TO, Barton, ER, Morris, LD, Whittemore, LA, Ahima, RS et al. (2002). Functional improvement of dystrophic muscle by myostatin blockade. Nature 420:418-421.
23. Whittemore, LA, Song, K, Li, X, Aghajanian, J, Davies, M, Girgenrath, S et al. (2003). Inhibition of myostatin in adult mice increases skeletal muscle mass and strength. Biochem Biophys Res Commun 300:965-971.
24. Bogdanovich, S, McNally, EM and Khurana, TS (2008). Myostatin blockade improves function but not histopathology in a murine model of limb-girdle muscular dystrophy 2C. Muscle Nerve 37:308-316.
25. Wagner, KR, Fleckenstein, JL, Amato, AA, Barohn, RJ, Bushby, K, Escolar, DM et al. (2008). A phase I/IItrial of MYO-029 in adult subjects with muscular dystrophy. Ann Neurol 63:561-571.
26. Bartoli, M, Poupiot, J, Vulin, A, Fougerousse, F, Arandel, L, Daniele, N et al. (2007). AAV-mediated delivery of a mutated myostatin propeptide ameliorates calpain 3 but not alpha-sarcoglycan deficiency. Gene Ther 14:733-740.
27. Bogdanovich, S, Perkins, KJ, Krag, TO, Whittemore, LA and Khurana, TS (2005). Myostatin propeptide-mediated amelioration of dystrophic pathophysiology. FASEB J 19:543-549.
28. Lee, SJ (2007). Quadrupling muscle mass in mice by targeting TGF-beta signaling pathways. PLoS ONE 2: e789.
29. Nakatani, M, Takehara, Y, Sugino, H, Matsumoto, M, Hashimoto, O, Hasegawa, Y et al. (2008). Transgenic expression of a myostatin inhibitor derived from follistatin increases skeletal muscle mass and ameliorates dystrophic pathology in mdx mice. FASEB J 22:477-487.
30. Qiao, C, Li, J, Jiang, J, Zhu, X, Wang, B, Li, J et al. (2008). Myostatin propeptide gene delivery by adeno-associated virus serotype 8 vectors enhances muscle growth and ameliorates dystrophic phenotypes in mdx mice. Hum Gene Ther 19:241-254.
31. Haidet, AM, Rizo, L, Handy, C, Umapathi, P, Eagle, A, Shilling, C et al. (2008). Long-term enhancement of skeletal muscle mass and strength by single gene administration of myostatin inhibitors. Proc Natl Acad Sci USA 105:4318-4322.
32. Miller, TM, Kim, SH, Yamanaka, K, Hester, M, Umapathi, P, Arnson, H et al. (2006). Gene transfer demonstrates that muscle is not a primary target for non-cell-autonomous toxicity in familial amyotrophic lateral sclerosis. Proc Natl Acad Sci USA 103:19546-19551.
33. Matsakas, A, Foster, K, Otto, A, Macharia, R, Elashry, MI, Feist, S et al. (2009). Molecular, cellular and physiological investigation of myostatin propeptide-mediated muscle growth in adult mice. Neuromuscul Disord 19:489-499.
34. Foster, K, Graham, IR, Otto, A, Foster, H, Trollet, C, Yaworsky, PJ et al. (2009). Adeno-associated virus-8-mediated intravenous transfer of myostatin propeptide leads to systemic functional improvements of slow but not fast muscle. Rejuvenation Res 12:85-94.
35. Li, Z, Zhao, B, Kim, YS, Hu, CY and Yang, J (2010). Administration of a mutated myostatin propeptide to neonatal mice significantly enhances skeletal muscle growth. Mol Reprod Dev 77:76-82.
36. Magee, TR, Artaza, JN, Ferrini, MG, Vernet, D, Zuniga, FI, Cantini, L et al. (2006). Myostatin short interfering hairpin RNA gene transfer increases skeletal muscle mass. J Gene Med 8:1171-1181.
37. Elbashir, SM, Lendeckel, W and Tuschl, T (2001). RNA interference is mediated by 21-and 22-nucleotide RNAs. Genes Dev 15:188-200. (Pubitemid 32107664)
38. Leung, RK and Whittaker, PA (2005). RNA interference: from gene silencing to gene-specific therapeutics. Pharmacol Ther 107:222-239.
39. Brummelkamp, TR, Bernards, R and Agami, R (2002). A system for stable expression of short interfering RNAs in mammalian cells. Science 296:550-553.
40. Watchko, J, O'Day, T, Wang, B, Zhou, L, Tang, Y, Li, J et al. (2002). Adeno-associated virus vector-mediated minidystrophin gene therapy improves dystrophic muscle contractile function in mdx mice. Hum Gene Ther 13:1451-1460.
41. Abmayr, S, Gregorevic, P, Allen, JM and Chamberlain, JS (2005). Phenotypic improvement of dystrophic muscles by rAAV/microdystrophin vectors is augmented by Igf1 codelivery. Mol Ther 12:441-450.
42. McPherron, AC, Lawler, AM and Lee, SJ (1997). Regulation of skeletal muscle mass in mice by a new TGF-beta superfamily member. Nature 387:83-90.
43. Mendias, CL, Marcin, JE, Calerdon, DR and Faulkner, JA (2006). Contractile properties of EDL and soleus muscles of myostatin-deficient mice. J Appl Physiol 101:898-905.
44. Zhu, X, Hadhazy, M, Wehling, M, Tidball, JG and McNally, EM (2000). Dominant negative myostatin produces hypertrophy without hyperplasia in muscle. FEBS Lett 474:71-75.
45. Lee, SJ, Reed, LA, Davies, MV, Girgenrath, S, Goad, ME, Tomkinson, KN et al. (2005). Regulation of muscle growth by multiple ligands signaling through activin type II receptors. Proc Natl Acad Sci USA 102:18117-18122.
46. Souza, TA, Chen, X, Guo, Y, Sava, P, Zhang, J, Hill, JJ et al. (2008). Proteomic identification and functional validation of activins and bone morphogenetic protein 11 as candidate novel muscle mass regulators. Mol Endocrinol 22:2689-2702.
47. Amthor, H, Otto, A, Vulin, A, Rochat, A, Dumonceaux, J, Garcia, L et al. (2009). Muscle hypertrophy driven by myostatin blockade does not require stem/precursor-cell activity. Proc Natl Acad Sci USA 106:7479-7484.
48. Vignaud, A, Caruelle, JP, Martelly, I and Ferry, A (2006). Differential effects of post-natal development, animal strain and long term recovery on the restoration of neuromuscular function after neuromyotoxic injury in rat. Comp Biochem Physiol C Toxicol Pharmacol 143:1-8.
49. Vignaud, A, Noirez, P, Besse, S, Rieu, M, Barritault, D and Ferry, A (2003). Recovery of slow skeletal muscle after injury in the senescent rat. Exp Gerontol 38:529-537.